CN1167707C - 作为细胞粘连抑制剂的单糖的2,3-o-异亚丙基衍生物 - Google Patents

作为细胞粘连抑制剂的单糖的2,3-o-异亚丙基衍生物 Download PDF

Info

Publication number
CN1167707C
CN1167707C CNB008048525A CN00804852A CN1167707C CN 1167707 C CN1167707 C CN 1167707C CN B008048525 A CNB008048525 A CN B008048525A CN 00804852 A CN00804852 A CN 00804852A CN 1167707 C CN1167707 C CN 1167707C
Authority
CN
China
Prior art keywords
isopropylidene
furanose
methyl
wood
deoxidation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008048525A
Other languages
English (en)
Chinese (zh)
Other versions
CN1343213A (zh
Inventor
Sk
S·K·阿罗拉
N·基肖尔
J·B·古普塔
ϣ
V·D·乔希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of CN1343213A publication Critical patent/CN1343213A/zh
Application granted granted Critical
Publication of CN1167707C publication Critical patent/CN1167707C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CNB008048525A 1999-01-15 2000-01-10 作为细胞粘连抑制剂的单糖的2,3-o-异亚丙基衍生物 Expired - Fee Related CN1167707C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN86/DEL/99 1999-01-15
IN86DE1999 IN190975B (cg-RX-API-DMAC7.html) 1999-01-15 1999-01-15
US09/276,368 US6590085B1 (en) 1999-01-15 1999-03-25 Derivatives of monosaccharides as cell adhesion inhibitors
US09/276,368 1999-03-25

Publications (2)

Publication Number Publication Date
CN1343213A CN1343213A (zh) 2002-04-03
CN1167707C true CN1167707C (zh) 2004-09-22

Family

ID=11088155

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008048525A Expired - Fee Related CN1167707C (zh) 1999-01-15 2000-01-10 作为细胞粘连抑制剂的单糖的2,3-o-异亚丙基衍生物

Country Status (30)

Country Link
US (5) US6590085B1 (cg-RX-API-DMAC7.html)
EP (1) EP1147119B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002534530A (cg-RX-API-DMAC7.html)
CN (1) CN1167707C (cg-RX-API-DMAC7.html)
AR (1) AR022235A1 (cg-RX-API-DMAC7.html)
AT (1) ATE250074T1 (cg-RX-API-DMAC7.html)
AU (1) AU768511B2 (cg-RX-API-DMAC7.html)
BG (1) BG105745A (cg-RX-API-DMAC7.html)
BR (1) BR0007553A (cg-RX-API-DMAC7.html)
CA (1) CA2359986A1 (cg-RX-API-DMAC7.html)
CO (1) CO5180591A1 (cg-RX-API-DMAC7.html)
CR (1) CR6423A (cg-RX-API-DMAC7.html)
CZ (1) CZ20012540A3 (cg-RX-API-DMAC7.html)
DE (1) DE60005300T2 (cg-RX-API-DMAC7.html)
DK (1) DK1147119T3 (cg-RX-API-DMAC7.html)
ES (1) ES2206176T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20010529B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0105116A3 (cg-RX-API-DMAC7.html)
ID (1) ID30351A (cg-RX-API-DMAC7.html)
IN (1) IN190975B (cg-RX-API-DMAC7.html)
MA (1) MA25342A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA01007187A (cg-RX-API-DMAC7.html)
MY (1) MY121135A (cg-RX-API-DMAC7.html)
NZ (2) NZ512852A (cg-RX-API-DMAC7.html)
PA (1) PA8489901A1 (cg-RX-API-DMAC7.html)
PT (1) PT1147119E (cg-RX-API-DMAC7.html)
SK (1) SK284241B6 (cg-RX-API-DMAC7.html)
TR (1) TR200102043T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000042054A1 (cg-RX-API-DMAC7.html)
YU (1) YU50701A (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN190975B (cg-RX-API-DMAC7.html) * 1999-01-15 2003-09-06 Ranbaxy Lab Ltd
NZ577031A (en) 2003-05-30 2010-09-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-CO inhibitors
WO2006024926A1 (en) * 2004-09-02 2006-03-09 Ranbaxy Laboratories Limited Monosaccharide derivatives
WO2007063356A2 (en) * 2004-12-22 2007-06-07 Ranbaxy Laboratories Limited Derivatives of pentose monosaccharides as anti-inflammatory compounds
US20090054519A1 (en) * 2005-07-22 2009-02-26 Abhijit Ray Derivatives of monosaccharides as 5-lipoxygenase inhibitors
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
US20080114031A1 (en) * 2006-03-29 2008-05-15 Sattigeri Viswajanani J Monosaccharide derivatives
EP1864992A2 (en) * 2006-05-30 2007-12-12 Ranbaxy Laboratories, Ltd. Monosaccharide derivatives
EP1953170A1 (en) * 2006-10-03 2008-08-06 Ranbaxy Laboratories Limited Monosaccharide derivatives as anti-inflammatory agents
AU2008221506B2 (en) * 2007-09-20 2011-01-20 ResMed Pty Ltd Retractable Tube for CPAP

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2715121A (en) 1950-09-09 1955-08-09 American Home Prod Alkyl sugar derivatives and their preparation
US4056322A (en) 1973-12-14 1977-11-01 Strategic Medical Research Corporation Preparation of ethers of monosaccharides
US4735934A (en) 1981-02-17 1988-04-05 Greenwich Pharmaceuticals Incorporated Method of therapeutically treating a warm blooded animal afflicted with an autoimmune disease
US4996195A (en) * 1989-01-09 1991-02-26 Greenwich Pharmaceuticals Inc. Derivatives of α,D-glucofuranose or α,D-allofuranose and intermediates for preparing these derivatives
US5010058A (en) * 1989-06-22 1991-04-23 501 Greenwich Pharmaceuticals Incorporated 3,5,6-substituted derivatives of 1,2-O-isopropylidene-α,D-glucofuranose and intermediates for preparing these derivatives
FR2652540B1 (fr) 1989-10-02 1995-06-02 Imaje Sa Circuit d'encre notamment destine a la mise en pression d'une encre a pigments pour imprimante a jet d'encre.
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5258402A (en) 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5432163A (en) 1992-11-13 1995-07-11 Greenwich Pharmaceuticals Incorporated Anti-proliferative and anti-inflammatory compounds: derivatives of pentose monosaccharides
US5637570A (en) * 1995-05-09 1997-06-10 Chemora Pharmochem Disubstituted and trisubstituted derivatives of 2,3:4,6-di-O-isopropylidene-α-L-xylo-2-hexulofuranosonic acid having anti-cancer, anti-inflammatory and anti-proliferative activity
IN190975B (cg-RX-API-DMAC7.html) * 1999-01-15 2003-09-06 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
BR0007553A (pt) 2001-12-18
US7005422B2 (en) 2006-02-28
US6590085B1 (en) 2003-07-08
TR200102043T2 (tr) 2001-11-21
AU1886100A (en) 2000-08-01
CZ20012540A3 (cs) 2002-02-13
DE60005300D1 (de) 2003-10-23
ATE250074T1 (de) 2003-10-15
CA2359986A1 (en) 2000-07-20
US20040029820A1 (en) 2004-02-12
DK1147119T3 (da) 2004-01-19
MXPA01007187A (es) 2002-04-24
WO2000042054A1 (en) 2000-07-20
SK10132001A3 (sk) 2002-01-07
EP1147119A1 (en) 2001-10-24
PA8489901A1 (es) 2000-09-29
AU768511B2 (en) 2003-12-18
HK1041270A1 (en) 2002-07-05
IN190975B (cg-RX-API-DMAC7.html) 2003-09-06
HRP20010529A2 (en) 2002-08-31
EP1147119B1 (en) 2003-09-17
US20040019191A1 (en) 2004-01-29
US20040018995A1 (en) 2004-01-29
US7037899B2 (en) 2006-05-02
JP2002534530A (ja) 2002-10-15
CR6423A (cg-RX-API-DMAC7.html) 2004-03-09
US7005516B2 (en) 2006-02-28
ID30351A (id) 2001-11-22
PT1147119E (pt) 2004-02-27
DE60005300T2 (de) 2004-07-15
MA25342A1 (fr) 2001-12-31
AR022235A1 (es) 2002-09-04
CN1343213A (zh) 2002-04-03
HUP0105116A3 (en) 2003-05-28
MY121135A (en) 2005-12-30
US20040023900A1 (en) 2004-02-05
BG105745A (en) 2002-05-31
HUP0105116A2 (hu) 2003-04-28
HRP20010529B1 (en) 2005-02-28
YU50701A (sh) 2005-06-10
NZ512852A (en) 2004-02-27
CO5180591A1 (es) 2002-07-30
ES2206176T3 (es) 2004-05-16
SK284241B6 (en) 2004-11-03
NZ527483A (en) 2005-02-25

Similar Documents

Publication Publication Date Title
CN1768072A (zh) 糖脂衍生物及其制造方法,以及其合成中间体及其制造方法
CN1198613C (zh) 氨基苯氧基乙酸衍生物和含有它们的药用组合物
CN1257891C (zh) 含氮五员环化合物
CN1098263C (zh) 吡啶－2－基－甲胺衍生物、其制备方法及其作为药物的用途
CN1192773C (zh) 环胺ccr3拮抗剂
CN1254478C (zh) 作为细胞吸附抑制剂的单糖衍生物
CN1699343A (zh) 盐酸多奈哌齐的多晶型物及其制备方法
CN1269833C (zh) 新的芳香酰胺、其制备方法以及作为药物的应用
CN1197458A (zh) 具有磷酯酶a2抑制活性的吡咯烷衍生物
CN1780621A (zh) 作为γ分泌酶抑制剂的磺酰胺衍生物
CN1106017A (zh) 核苷酸膦酸酯衍生物
CN1331688A (zh) 氨基吡啶衍生物
CN1658875A (zh) 用作组胺h3拮抗剂的1－(4－哌啶基)苯并咪唑酮
CN1167707C (zh) 作为细胞粘连抑制剂的单糖的2,3-o-异亚丙基衍生物
CN101050194A (zh) 双环辛烷类衍生物、其制备方法及其在医药上的用途
CN1211244A (zh) 根赤壳菌素衍生物
CN87108160A (zh) 制备和应用具有活性羰基的唾液酸衍生物的方法
CN1208318C (zh) 环胺ccr5受体拮抗剂
CN1976901A (zh) 新的芳脒衍生物、其盐、及含有这些的抗真菌剂
CN86104787A (zh) 制备聚-4-氨基吡咯-2-甲酰胺基衍生物的方法
CN1254334A (zh) 新颖的对苯二甲酰胺衍生物
CN1099033A (zh) 吡唑并[4，3-c]吡啶，它们的制备方法及其作为5-羟色胺再摄入抑制剂的用途
CN1642932A (zh) 单糖的端基异构衍生物
CN1027536C (zh) 4，5，6，7-四氢化苯并咪唑衍生物制备方法
CN1656095A (zh) 螺衍生物和包含其作为活性组分的粘着分子抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee